A 62-year-old man with newly diagnosed Parkinson's disease presents with bradykinesia and rigidity. He has no cognitive impairment and normal renal function. Which is the drug of choice for initial monotherapy in this patient?

Explanation

## First-Line Monotherapy in Early Parkinson's Disease **Key Point:** Levodopa with a peripheral decarboxylase inhibitor (carbidopa or benserazide) remains the gold standard and most effective drug for symptomatic management of Parkinson's disease, especially when motor symptoms are functionally disabling. ### Why Levodopa + Carbidopa? 1. **Efficacy**: Most potent antiparkinsonian agent; directly replaces depleted dopamine in the striatum 2. **Rapid onset**: Symptom relief within days to weeks 3. **Broad spectrum**: Effective against all cardinal features (bradykinesia, rigidity, tremor, postural instability) 4. **Carbidopa role**: Peripheral decarboxylase inhibitor that prevents premature conversion of levodopa to dopamine in the periphery, reducing GI side effects and increasing CNS bioavailability ### Comparison with Alternatives | Drug | Onset | Efficacy | Role | Limitation | |------|-------|----------|------|------------| | Levodopa + carbidopa | Days–weeks | Excellent (gold standard) | First-line monotherapy | Motor fluctuations, dyskinesias with prolonged use | | Bromocriptine | Weeks | Moderate | Second-line; dopamine agonist | Ergot-derived; fibrosis risk; less effective than levodopa | | Selegiline | Weeks–months | Mild | Adjunctive; MAO-B inhibitor | Weak monotherapy; mainly delays levodopa need | | Amantadine | Days–weeks | Mild | Adjunctive; NMDA antagonist | Weak monotherapy; mainly for dyskinesias | **High-Yield:** In early PD with functional disability, levodopa + carbidopa is preferred over dopamine agonists because it provides superior motor control. Dopamine agonists are reserved for younger patients (<50 years) to delay motor complications, or as adjuncts in advanced disease. **Clinical Pearl:** The fear of "levodopa toxicity" or early introduction causing motor complications is largely unfounded. Current evidence supports early use when symptoms warrant treatment; motor fluctuations are more related to disease progression and dopamine neuron loss than to levodopa exposure itself. **Warning:** Do not confuse levodopa monotherapy with levodopa + carbidopa. Levodopa alone causes severe nausea and peripheral dopamine effects; carbidopa is essential to block peripheral conversion.